Custom service
LNP-mRNA-based Antibody Production Platform
Antigen expressed in vivo, from an mRNA delivered to the draining node.
mRNA delivered in a lipid nanoparticle does what DNA immunisation does, faster and with a different adjuvant profile. The mRNA is translated in the cytoplasm of cells at the injection site and in the draining lymph node, the encoded antigen is presented with native folding and glycosylation, and the lipid carrier itself provides an innate immune stimulus that removes the need for a separate adjuvant.
The practical advantages are speed and flexibility. A construct can be designed, synthesised and formulated in two to three weeks, and several antigens can be encoded on separate mRNAs and mixed into a single injection — useful when a project needs antibodies against a receptor and its close homologue for counter-screening, or against several variants of a viral protein. Expression is transient, lasting days, which suits repeated dosing without sustained antigen exposure.
The platform is not a universal replacement for protein immunisation. Titres are often lower, the response is Th1-skewed, and the technology adds cost per animal. It earns its place for membrane proteins, for antigens that are difficult to produce, and for projects where the timeline from sequence to first bleed is the deciding factor.
Service Highlights
Where it fits
The platform suits difficult membrane targets, antigens that resist recombinant expression, and projects that need antibodies against several related sequences at once. It is also a reasonable choice when a DNA construct is available but gene gun delivery is not practical for the host species.
It is a poor choice when the highest possible titre is required within a short window — protein with a strong adjuvant still wins there — and when the project cannot absorb the added cost of mRNA synthesis and LNP formulation.
Documentation and QC
Each batch of mRNA is checked for integrity, capping efficiency and endotoxin, and each LNP preparation for size, polydispersity and encapsulation. Expression is confirmed in HEK293 cells before dosing. Screening data, isotype and sequence are reported as for any hybridoma campaign.
Frequently asked questions
How does this compare with DNA immunisation?
mRNA reaches the cytoplasm directly, so there is no nuclear entry barrier and expression begins within hours. Responses are usually faster and somewhat stronger, at a higher cost per dose.
Can several antigens be combined?
Yes, up to four mRNAs in one formulation, provided the antigens are compatible in size and formulation. Screening then needs to distinguish them, which is done with individual recombinant proteins.
Is the LNP itself immunogenic?
The ionisable lipid provides an adjuvant effect through innate immune sensing, which is part of why no additional adjuvant is used. It also means reactogenicity at the injection site should be expected and is monitored.
Send the sequences and tell us how many antigens the campaign must cover. If a recombinant protein already exists, a protein route may still be cheaper — we will compare both before starting.
Service Highlights
- Sequence to injection in three weeks. Codon-optimised mRNA synthesised by IVT, capped, purified by cellulose or HPLC, and formulated into ionisable LNPs.
- Native antigen presentation. The encoded protein is folded and glycosylated by the animal's own machinery, including transmembrane topology.
- Multiplexed immunisation. Two to four antigens mixed in one injection, with separate readouts at screening.
- Formulation control. Particle size 80–120 nm, PDI below 0.2, and encapsulation efficiency above 90%, measured before dosing.
- Tunable schedule. Repeated dosing at 10–14 day intervals, with the option of a protein boost before fusion.
- Documented expression. In vitro translation and cell transfection confirm antigen expression before animals are dosed.
How the work runs
Antigen design and IVT template
Sequence optimisation, signal peptide and topology decisions, then a linear template for in vitro transcription.
mRNA synthesis and QC
IVT with modified nucleotides, 5' cap and poly(A) tail, purification, and integrity checked by agarose gel and capillary electrophoresis.
LNP formulation
Microfluidic mixing with ionisable lipid, helper lipid, cholesterol and PEG-lipid; size, PDI and encapsulation efficiency measured.
Immunisation
Intramuscular or subcutaneous dosing at 5–20 µg per animal, three to four times at 10–14 day intervals, with serum titre monitored.
Fusion and screening
Standard fusion; screening by ELISA on recombinant protein or by flow on transfected cells, depending on the target class.
Cloning and delivery
Subcloning, isotyping, scale-up, and supply of the mRNA template for any future boost.
Specifications & timeline
- Timeline
- 8–12 weeks — to screening
- Dose
- 5–20 µg mRNA — per injection
- Advantage
- Multiplex — several antigens per campaign
- mRNA
- IVT with N1-methylpseudouridine, 5' cap 1 structure, 100–150 nt poly(A)
- LNP
- Ionisable lipid formulation, 80–120 nm, PDI <0.2, encapsulation >90%
- Dose
- 5–20 µg mRNA per injection, 3–4 doses
- Timeline
- 8–12 weeks from sequence to validated hybridoma
- Species
- Mouse, rat, rabbit
- Deliverables
- 2–5 hybridomas, mRNA template, formulation QC data, isotype and screening report
Related Products
- Recombinant ProteinsGrowth factors, cytokines and antigens produced across E. coli, yeast, insect and mammalian hosts — over 10,000 items on the shelf and ready to move.
- Native ProteinsIsolated directly from natural sources, preserving native post-translational modifications and conformational epitopes that recombinant systems can miss.
- Monoclonal AntibodiesRecombinant and hybridoma clones characterised for Western blot, IHC, immunofluorescence, ELISA and flow cytometry — application data included.
Next step
Tell us the target, we will tell you what is feasible
Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.